Chimerix, Inc. (CMRX) Rating Lowered to Sell at ValuEngine

ValuEngine downgraded shares of Chimerix, Inc. (NASDAQ:CMRX) from a hold rating to a sell rating in a research note issued to investors on Friday.

CMRX has been the subject of several other research reports. Zacks Investment Research raised shares of Chimerix from a hold rating to a buy rating and set a $5.25 price target for the company in a research report on Wednesday. Cowen and Company reissued a hold rating and set a $6.00 price target on shares of Chimerix in a research report on Friday, April 28th. Finally, FBR & Co reissued a hold rating and set a $7.00 price target on shares of Chimerix in a research report on Monday, May 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $7.56.

Shares of Chimerix (CMRX) traded up 1.79% during mid-day trading on Friday, reaching $4.54. The company had a trading volume of 168,976 shares. Chimerix has a 12-month low of $3.66 and a 12-month high of $6.64. The company’s market capitalization is $213.59 million. The firm has a 50-day moving average of $5.11 and a 200-day moving average of $5.43.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $1.28 million. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%. On average, equities analysts anticipate that Chimerix will post ($1.68) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://sportsperspectives.com/2017/08/12/chimerix-inc-cmrx-rating-lowered-to-sell-at-valuengine.html.

Several large investors have recently made changes to their positions in CMRX. Teza Capital Management LLC purchased a new stake in shares of Chimerix during the first quarter valued at $135,000. American International Group Inc. increased its stake in shares of Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 1,733 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Chimerix during the second quarter valued at $185,000. Trexquant Investment LP purchased a new stake in shares of Chimerix during the first quarter valued at $226,000. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in shares of Chimerix during the first quarter valued at $226,000. 65.63% of the stock is owned by institutional investors.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply